Holen Sie sich die Stockscreener-App
7.2679
2.94%
0.2079
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Aug Setups: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Understanding the Setup: (ARCT) and Scalable Risk - Stock Traders Daily
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf - MarketBeat
Arcturus Therapeutics at the 38th Annual Roth Conference: Strategic Shift to Rare Diseases - Investing.com Canada
These Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley Fool
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data - MSN
ARCT Stock Price, Quote & Chart | ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) - ChartMill
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 earnings call transcript - MSN
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial - MarketBeat
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
B Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with buy recommendation - MSN
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics By Investing.com - Investing.com Australia
Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
ARCT: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
Arcturus Therapeutics stresses importance of phased clinical trials in drug development - Traders Union
Update Recap: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Can Arcturus Therapeutics Holdings Inc sustain its profitabilityMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn
The Technical Signals Behind (ARCT) That Institutions Follow - Stock Traders Daily
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - MarketBeat
Patients and scientists join forces for rare disease progress, Arcturus Therapeutics asserts - Traders Union
ARCT Should I Buy - Intellectia AI
Arcturus (ARCT) Q4 2025 Earnings Call Transcript - AOL.com
Stock Report: Can Arcturus Therapeutics Holdings Inc sustain its profitabilityJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Arcturus Therapeutics: Downgrading to "Hold" As CF Program Shifts Population Focus (ARCT) - Seeking Alpha
Arcturus Therapeutics to attend Leerink Partners 2026 Global Healthcare Conference - Traders Union
Q1 EPS Forecast for Arcturus Therapeutics Reduced by Analyst - MarketBeat
Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Citigroup Lowers Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - PharmiWeb.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript - Insider Monkey
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026 - Meyka
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative - simplywall.st
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Piper Sandler Lowers Price Target for Arcturus Therapeutics (ARC - GuruFocus
New nasal vaccine protects lungs for months against viruses, bacteria, and allergens - AOL.com
Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00 - MarketBeat
Arcturus Therapeutics reports financial results and pipeline progress - Traders Union
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline P - PharmiWeb.com
Earnings call transcript: Arcturus Q4 2025 misses expectations, stock drops By Investing.com - Investing.com South Africa
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):